Viking shares soar as liver disease drug succeeds in mid-stage study
Viking Therapeutics Inc's shares more than doubled on Tuesday after its experimental liver disease treatment met the goals of a mid-stage trial by lowering cholesterol and liver fat levels in patients.
from Reuters: Health News https://reut.rs/2NlYw4H
http://bit.ly/2zwRqiM